RE:A Question for any Shorts on this siteSkyplt, I'm not a shorter here (or anywhere for that matter). After reading an article regarding CIBC and it being a 'hot mess' when it comes to their investment strategy in cannabis sector, I've come to a conclusion that the banks picked their winner (or, winners?) many moons ago and APHA does not seem to be one of them. And somehow, somewhere (putting on a tin foil hat), DD approval may be a part of the whole mystery of why it's taking forever to get an approval).
So, who is the banks' favorite child? It's quite obvious to me and let me start with I cannot think of any explanation why WEED (with a fired CEO, poor sales and years-to-profitability) would still be in $30-range. The same applies to ACB with billion shares and still not profitable. Even CRON with its backing of Altria is vulnerable to large drops in stock price. But, that's their problem. Our issue is APHA's stock price that defies the logic, right? One does not need to go far to see who the main culprit is behind the APHA stock price manipulation: 079.
I wish all the best to APHA, yet I think we'll have to be very, very patient. I sincerely hope that the next quarterly results will be as good or even better than the previous ones. A few quarters like that and the earnings should prove APHA's worth. Hopefully, a partner will come along that will get this stigma off of APHA. Otherwise, I think this pattern of slow bleeding without any reason behind it will repeat itself over and over again.